Search research articles
Contact Us
Filters
Showing results (121-130 of 418) with videos related to
Page
of 42
Sort By:
The Journal of Investigative Dermatology
|
December 17, 2008
Inhibition of PI3K-AKT-mTOR signaling sensitizes melanoma cells to cisplatin and temozolomide
Tobias Sinnberg, Konstantinos Lasithiotakis, Heike Niessner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 14, 2011
Major response to everolimus in melanoma with acquired imatinib resistance
Lu Si, Xiaowei Xu, Yan Kong, et al.
Journal of Neuro-Oncology
|
April 13, 2015
Survival patterns following brain metastases for patients with melanoma in the MAP-kinase inhibitor era
Daniel A Wattson, Ryan J Sullivan, Andrzej Niemierko, et al.
JAMA Oncology
|
March 10, 2017
Adjuvant Treatment for High-Risk Clear Cell Renal Cancer: Updated Results of a High-Risk Subset of the ASSURE Randomized Trial
Naomi B Haas, Judith Manola, Janice P Dutcher, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 19, 2012
Phase III trial of carboplatin and paclitaxel with or without sorafenib in metastatic melanoma
Keith T Flaherty, Sandra J Lee, Fengmin Zhao, et al.
The Journal of Investigative Dermatology
|
February 9, 2016
Promoter Methylation of PTEN Is a Significant Prognostic Factor in Melanoma Survival
Mi Ryung Roh, Sameer Gupta, Kyu-Hyun Park, et al.
AJR. American Journal of Roentgenology
|
December 21, 2012
MRI assessment of early tumor response in metastatic renal cell carcinoma patients treated with sorafenib
Hyunseon Christine Kang, Kay-See Tan, Stephen M Keefe, et al.
Investigational New Drugs
|
December 18, 2009
Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a Phase II randomized discontinuation trial
Simon Pacey, Mark J Ratain, Keith T Flaherty, et al.
The Oncologist
|
June 19, 2015
Phase I/II Trial of Imatinib and Bevacizumab in Patients With Advanced Melanoma and Other Advanced Cancers
Keith T Flaherty, Betty K Hamilton, Mark A Rosen, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 8, 2019
Effect of concomitant dosing with acid-reducing agents and vemurafenib dose on survival in patients with BRAF<sup>V600</sup> mutation-positive metastatic melanoma treated with vemurafenib ± cobimetinib
Karl Lewis, Axel Hauschild, James Larkin, et al.
Page
of 42
Search research articles
Search
Showing results (121-130 of 418) with videos related to
Sort By:
Page
of 42
The Journal of Investigative Dermatology
|
December 17, 2008
Inhibition of PI3K-AKT-mTOR signaling sensitizes melanoma cells to cisplatin and temozolomide
Tobias Sinnberg, Konstantinos Lasithiotakis, Heike Niessner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 14, 2011
Major response to everolimus in melanoma with acquired imatinib resistance
Lu Si, Xiaowei Xu, Yan Kong, et al.
Journal of Neuro-Oncology
|
April 13, 2015
Survival patterns following brain metastases for patients with melanoma in the MAP-kinase inhibitor era
Daniel A Wattson, Ryan J Sullivan, Andrzej Niemierko, et al.
JAMA Oncology
|
March 10, 2017
Adjuvant Treatment for High-Risk Clear Cell Renal Cancer: Updated Results of a High-Risk Subset of the ASSURE Randomized Trial
Naomi B Haas, Judith Manola, Janice P Dutcher, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 19, 2012
Phase III trial of carboplatin and paclitaxel with or without sorafenib in metastatic melanoma
Keith T Flaherty, Sandra J Lee, Fengmin Zhao, et al.
The Journal of Investigative Dermatology
|
February 9, 2016
Promoter Methylation of PTEN Is a Significant Prognostic Factor in Melanoma Survival
Mi Ryung Roh, Sameer Gupta, Kyu-Hyun Park, et al.
AJR. American Journal of Roentgenology
|
December 21, 2012
MRI assessment of early tumor response in metastatic renal cell carcinoma patients treated with sorafenib
Hyunseon Christine Kang, Kay-See Tan, Stephen M Keefe, et al.
Investigational New Drugs
|
December 18, 2009
Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a Phase II randomized discontinuation trial
Simon Pacey, Mark J Ratain, Keith T Flaherty, et al.
The Oncologist
|
June 19, 2015
Phase I/II Trial of Imatinib and Bevacizumab in Patients With Advanced Melanoma and Other Advanced Cancers
Keith T Flaherty, Betty K Hamilton, Mark A Rosen, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 8, 2019
Effect of concomitant dosing with acid-reducing agents and vemurafenib dose on survival in patients with BRAF<sup>V600</sup> mutation-positive metastatic melanoma treated with vemurafenib ± cobimetinib
Karl Lewis, Axel Hauschild, James Larkin, et al.
Page
of 42